Last updated: June 29, 2026
ecutive summary
Liquidia Technologies Inc. litigation against United Therapeutics Corp. in No. 1:25-cv-00299 centers on alleged infringement tied to United Therapeutics’ pulmonary arterial hypertension (PAH) portfolio. The case’s commercial and regulatory impact will depend on (i) which patents Liquidia asserted, (ii) whether the asserted patents are listed in the relevant FDA Orange Book(s), and (iii) whether the dispute is stayed or consolidated with other related PAH patent cases. Without the underlying complaint, docket events, asserted patent list, and the specific accused United Therapeutics product(s), a complete, accurate infringement, validity, and remedy analysis cannot be produced.
Liquidia v. United Therapeutics 1:25-cv-00299 litigation summary: what does the case allege?
A litigation summary requires the operative pleading contents: asserted patent numbers, the specific accused product(s), the asserted claims, infringement theory (literal, doctrine of equivalents), and any marking/notice allegations. Those facts are not present in the information provided.
What patents does Liquidia assert in 1:25-cv-00299?
A patent-level summary must list each asserted patent, its priority and expiration framework (including PTA/PTE effects where applicable), claim categories (composition, formulation, device, method-of-use, or manufacturing), and the litigation claim mapping themes. The asserted patent list is not provided.
Which United Therapeutics products are accused in 1:25-cv-00299?
A product-level infringement analysis depends on identifying:
- the dosage form and route (e.g., inhalation vs oral)
- formulation attributes (particle size, excipient system, device integration)
- labeling and intended use tied to method claims
The accused product(s) are not provided.
How strong are Liquidia’s asserted patents in Liquidia Technologies v. United Therapeutics (1:25-cv-00299)?
A strength analysis in Hatch-Waxman-style disputes typically covers:
- novelty and nonobviousness posture at filing
- claim breadth against prior art
- prosecution history estoppel risk
- enablement and written description support
- enforceability defenses (inequitable conduct, subject matter eligibility where relevant)
None of this can be performed accurately without the patents-in-suit, claim excerpts, and the accused product/formulation details.
What claim types are typically at issue in Liquidia PAH disputes?
In Liquidia’s historical PAH litigation posture, asserted estates commonly target one or more of:
- microparticle or nanoparticle formulation systems
- spray-dried or engineered powder manufacturing and particle properties
- sustained-release or controlled-release inhalation delivery characteristics
- method-of-use tied to dosing regimens and patient subpopulations
This pattern cannot be assumed for case 1:25-cv-00299 without the complaint.
What does the litigation posture indicate for FDA exclusivity and Orange Book status?
To assess exclusivity and Orange Book status, the analysis must link each asserted patent to the relevant FDA listing for the specific drug product and strength categories used by FDA (Orange Book listing type and patent expiration dates). No Orange Book listing identifiers are provided.
What is the Orange Book status of the asserted patents?
Orange Book status requires, at minimum:
- drug product name(s) and applicant/labeler
- listed patents and their listing codes
- patent expiration dates and any pediatric exclusivity extensions
Those inputs are not provided.
When does exclusivity end for the accused United Therapeutics product(s)?
A timeline requires the applicable exclusivity (NCE/505(b)(2), BLA exclusivity if biologic, 3-year/5-year exclusivity where relevant, and any pediatric extension) plus patent expiration dates. No product identity or exclusivity details are provided.
What defenses does United Therapeutics raise in 1:25-cv-00299?
A defense map requires the answer, any Rule 12 motions, invalidity contentions, and claim construction positions. Common defenses include:
- noninfringement (no meeting claim limitations)
- invalidity (anticipation, obviousness, lack of written description/enablement)
- unenforceability (inequitable conduct)
- procedural defenses (improper venue, jurisdiction, failure to state a claim)
Those specifics are not available.
What is the most likely outcome of Liquidia v. United Therapeutics (1:25-cv-00299) based on the docket?
Outcome forecasting depends on case events:
- motions to dismiss or transfer
- claim construction orders
- scheduling and discovery status
- preliminary injunction posture (if sought)
- settlement indicators
No docket events, hearings, or orders are provided.
Has United Therapeutics already settled related PAH patent cases, and how could that affect 1:25-cv-00299?
Settlement-driven analysis requires identifying:
- whether Liquidia’s estate has parallel litigation against the same accused product
- whether there are consent judgments, covenants not to sue, or license agreements
- whether other cases informed claim construction or invalidity findings
No settlement documents or related case cross-references are provided.
How does Liquidia’s case compare with other PAH patent estates targeting inhaled delivery?
A comparative analysis requires:
- the specific drug class and mechanism (e.g., inhaled prostacyclin pathway vs PDE5 vs endothelin pathway)
- the asserted technologies (formulation vs method)
- geographic scope (US only vs international parallel filings)
- similarity of particle/process parameters across disputes
The necessary facts tied to 1:25-cv-00299 are not included.
Key steps to monitor in 1:25-cv-00299 (litigation watchlist)
A litigation watchlist requires actual docket items. Without them, only generic items could be listed, which would not meet the requirement for “hard data and actionable insights.”
Key Takeaways
A litigation summary and analysis for Liquidia Technologies, Inc. v. United Therapeutics Corp., 1:25-cv-00299 cannot be completed to a business-useful standard without the operative pleading and docket facts (asserted patents, accused products, claims, infringement theories, defense posture, and procedural milestones).
FAQs
- What patents are asserted in Liquidia Technologies v. United Therapeutics, 1:25-cv-00299?
- Which United Therapeutics product(s) are accused in 1:25-cv-00299 and what dosage forms are implicated?
- How do asserted patent claims map to accused formulation or device limitations in 1:25-cv-00299?
- What Orange Book listings correspond to the asserted patents for the accused United Therapeutics product(s)?
- What docket events (claim construction, motions, injunction requests) control the litigation timeline in 1:25-cv-00299?
References (APA)
No cited sources were provided in the prompt content.
